Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2022 | The outcomes of patients with primary refractory and relapsed acute leukemia

Arnon Nagler • 12 Jun 2022
EHA 2022
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Leukemia

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, comments on the outcomes of patients with primary refractory and relapsed acute leukemia. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Arnon Nagler

Evaluating the impact of donor age on alloSCT outcomes in patients with secondary AML in CR1 2:01
Evaluating the impact of donor age on alloSCT outcomes in patients with secondary AML in CR1
Arnon Nagler • 6 Dec 2025
Transplanting patients with advanced AML 3:07
Transplanting patients with advanced AML
Arnon Nagler • 30 Mar 2025
Bone marrow versus mobilized peripheral blood grafts for haploidentical transplant in secondary AML 1:42
Bone marrow versus mobilized peripheral blood grafts for haploidentical transplant in secondary AML
Arnon Nagler • 30 Mar 2025
Is there a preferable donor for alloSCT in secondary AML in first complete remission? 2:23
Is there a preferable donor for alloSCT in secondary AML in first complete remission?
Arnon Nagler • 30 Mar 2025

Related Videos

Evaluation of real-world ventoclax initiation prophylaxis & monitoring outcomes in patients with CLL 2:31
Evaluation of real-world ventoclax initiation prophylaxis & monitoring outcomes in patients with CLL
Nilanjan Ghosh • 10 Dec 2025
BGB-16673 in patients with R/R CLL/SLL: updated results from the ongoing Phase I CaDAnCe-101 study 1:41
BGB-16673 in patients with R/R CLL/SLL: updated results from the ongoing Phase I CaDAnCe-101 study
Inhye Ahn • 6 Dec 2025
Enzomenib monotherapy in R/R AML: updated results from a Phase I/II study 2:30
Enzomenib monotherapy in R/R AML: updated results from a Phase I/II study
Naval Daver • 8 Dec 2025
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
The content of VJHemOnc is intended for healthcare professionals